They were results from the special access scheme (SAS). These will be ongoing for approx another 100 odd patients as data becomes available.
The main, more important trials are pasted below... Just copied from website...
Phase 2 clinical trial for patients with BMLs and Osteoarthritis
A phase 2b, randomised double blind placebo controlled multicentre study to evaluate the effects of pentosan polysulfate sodium on treating pain in subjects with osteoarthritis of the knee and subchondral bone marrow lesions.
Fifty one capital in their recent report suggested 18th Dec for these results... However in a tweet last Friday night that I posted on par threads they said only a week to wait... So were within days of the big news (for better or worse).
PAR chart, page-65
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.055(20.4%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 33.5¢ | 27.5¢ | $1.328M | 4.323M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 152597 | 4 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
